Last Updated on November 18, 2022 by GlobeNewsWire
NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandler’s 34th Annual Healthcare Conference, being held November 29 – December 1, 2022, in New York.
Avanish Vellanki, chief executive officer of Rain, will be participating in a fireside chat on Thursday, December 1 at 1:30 p.m. ET. A webcast of the fireside chat can be accessed here. The Company’s management team will participate in one-on-one investor meetings. To request a meeting, please contact your Piper Sandler representative.
About Rain Therapeutics Inc. Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Investor ContactDan FerryLifeSci Advisors+1.617.430.7576daniel@lifesciadvisors.com
Media Contact Jordyn Temperato LifeSci Communications jtemperato@lifescicomms.com
Leave a Reply